An observational study in Hutchinson-Gilford Progeria Syndrome, sponsored by Bundang CHA Hospital. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Bundang CHA Hospital · Observational
This study aims to establish induced pluripotent stem cell (iPSC) lines from the blood of one pediatric patient with Hutchinson-Gilford Progeria Syndrome (HGPS), a rare disease that causes rapid, premature aging, in order to build a laboratory model of the disease. The main purpose of this study is to collect a blood sample (a total of 9cc, drawn once) from the patient, reprogram the patient's blood cells into stem cells, and then differentiate these stem cells into disease-relevant cell types (such as fibroblasts, vascular smooth muscle cells, and neurons) to study how HGPS affects cells at a molecular level. These patient-derived cells will then be used entirely in the laboratory (in-vitro) to test the safety and effectiveness of candidate treatments, including an RNA-targeting gene therapy, before any such therapy would be considered for use in patients.
Bundang CHA Hospital is the lead sponsor of 35 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study will enroll a single pediatric patient with Hutchinson-Gilford Progeria Syndrome (HGPS) who is currently receiving outpatient follow-up care at the Department of Rehabilitation Medicine, CHA Bundang Medical Center. The patient was identified through routine clinical care at this institution; no external recruitment or advertisement will be used.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinically diagnosed with Hutchinson-Gilford Progeria Syndrome (HGPS) Currently followed as an outpatient at the study institution 19 years of age or younger at enrollment Able to provide written (or legal guardian able to provide consent on the patient's behalf) Willing and able to undergo a single peripheral blood draw for PBMC collection
Exclusion Criteria
Clinical condition precluding safe blood collection (e.g., severe anemia, active infection at the collection site, or a bleeding disorder) Patient or legal guardian unable or unwilling to provide Collected PBMCs yield insufficient quantity or viability for successful iPSC reprogramming (results in post-hoc exclusion from cell-based analysis only, not from study consent)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Established an induced pluripotent stem cell (iPSC) cell line.
Established an induced pluripotent stem cell (iPSC) cell line using peripheral blood mononuclear cells (PBMCs) obtained from patients with Hutchinson-Gilford Progeria Syndrome.
Time frame: Through study completion, an estimated 12 months from PBMC collection
No study locations are listed for this record.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Progeria
Bundang CHA Hospital